Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma

Immunology

Volumn 128, Issue 1, 2009, Pages 134-140

  Zhao, Fei ^a   Vermeer, Benjamin ^a   Lehmann, Ulrich ^b   Kreipe, Hans ^b   Manns, Michael P ^a   Korangy, Firouzeh ^a   Greten, Tim F ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibody; Immunotherapy; Pancreatic cancer; Tankyrase 2; Tumour antigen

Indexed keywords

CANCER ANTIBODY; TANKYRASE; TANKYRASE 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HUMANS; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TANKYRASES;

EID: 68249097075     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03090.x     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004 363 : 1049 57.
3. Merchant N, Berlin J. Past and future of pancreas cancer: are we ready to move forward together? J Clin Oncol 2008 26 : 3478 80.
4. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev 2005 5 : 459 67.
5. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer\testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002 188 : 22 32.
6. Jäger E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000 97 : 4760 5.
7. Jäger E, Jäger D, Karbach J et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101- 0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000 191 : 625 30.
8. Jäger E, Gnjatic S, Nagata Y et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000 97 : 12198 203.
9. Wagner M, Greten FR, Weber CK et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev 2001 15 : 286 93.
10. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002 123 : 2052 63.
11. Garbe AI, Vermeer B, Gamrekelashvili J et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 2006 66 : 508 16.
12. Wagner M, Luhrs H, Kloppel G, Adler G, Schmid RM. Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 1998 115 : 1254 62.
13. Christgen M, Bruchhardt H, Ballmaier M, Krech T, Langer F, Kreipe H, Lehmann U. KAI1\CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Int J Cancer 2008 123 : 2239 46.
14. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997 9 : 709 16.
15. Chen YT, Göre AO, Tsang S, Stockert E, Jäger E, Knuth A, Old LJ. Identification of multiple cancer\testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998 95 : 6919 23.
16. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004 10 : 4332 41.
17. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001 281 : 936 44.
18. Wadle A, Kubuschok B, Imig J et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 2006 119 : 117 25.
19. Thomas AM, Santarsiero LM, Lutz ER et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004 200 : 297 306.
20. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br J Cancer 2006 94 : 341 5.
21. Chi NW, Lodish HF. Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J Biol Chem 2000 275 : 38437 44.
22. Monz D, Munnia A, Comtesse N, Fischer U, Steudel WI, Feiden W, Glass B, Meese EU. Novel tankyrase-related gene detected with meningioma-specific sera. Clin Cancer Res 2001 7 : 113 9.
23. Kuimov AN, Kuprash DV, Petrov VN, Vdovichenko KK, Scanlan MJ, Jongeneel CV, Lagarkova MA, Nedospasov SA. Cloning and characterization of TNKL, a member of tankyrase gene family. Genes Immun 2001 2 : 52 5.
24. Cook BD, Dynek JN, Chang W, Shostak G, Smith S. Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol 2002 22 : 332 42.
25. Kaminker PG, Kim SH, Taylor RD, Zebarjadian Y, Funk WD, Morin GB, Yaswen P, Campisi J. TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J Biol Chem 2001 276 : 35891 9.
26. Chiang YJ, Nguyen ML, Gurunathan S, Kaminker P, Tessarollo L, Campisi J, Hodes RJ. Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice. Mol Cell Biol 2006 26 : 2037 43.
27. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008 222 : 162 79.
28. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004 16 : 143 50.